NCT01720303View on ClinicalTrials.gov

Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

September 19, 2002

Primary Completion Date

April 10, 2003

Study Completion Date

April 10, 2003

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

repaglinide

2 mg (tablets) before each main meal

DRUG

isophane human insulin

Injection s.c. (under the skin) at bedtime

DRUG

insulin

Injection s.c. (under the skin) twice daily

Trial Locations (3)

100101

Novo Nordisk Investigational Site, Beijing

200040

Novo Nordisk Investigational Site, Shanghai

200433

Novo Nordisk Investigational Site, Shanghai

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY